This content is in French.
Gene therapy: a turning point for parkinson’s disease?
7 avril 2026
By Ana Espino | Published on April 7, 2026 | 4 min readParkinson’s disease is a major progressive neurodegenerative disorder affecting more than 8.5 million people worldwide. Its incidence continues to rise, making it an increasing public health concern. The disease is characterized by the progressive degeneration of dopaminergic neurons in the substantia nigra, along with the accumulation of α-sy
By Ana Espino | Published on April 7, 2026 | 4 min read
Parkinson’s disease is a major progressive neurodegenerative disorder affecting more than 8.5 million people worldwide. Its incidence continues to rise, making it an increasing public health concern. The disease is characterized by the progressive degeneration of dopaminergic neurons in the substantia nigra, along with the accumulation of α-synuclein aggregates, leading to neuronal dysfunction.
Parkinson’s disease is a major progressive neurodegenerative disorder affecting more than 8.5 million people worldwide. Its incidence continues to rise, making it an increasing public health concern. The disease is characterized by the progressive degeneration of dopaminergic neurons in the substantia nigra, along with the accumulation of α-synuclein aggregates, leading to neuronal dysfunction.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Szunyogh S, et al. Recent developments in gene therapy for Parkinson's disease. Mol Ther. 2025 May 7;33(5):2052-2064. doi: 10.1016/j.ymthe.2025.03.030. Epub 2025 Mar 22. PMID: 40121531; PMCID: PMC12126811
View on PubMed
